| Bioactivity | D-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. D-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance [1]. |
| Name | D-K6L9 |
| CAS | 426264-61-1 |
| Sequence | Leu-Lys-{d-Leu}-Leu-Lys-{d-Lys}-Leu-{d-Leu}-{d-Lys}-Lys-Leu-Leu-{d-Lys}-Leu-Leu-NH2 |
| Shortening | LK-{d-Leu}-LK-{d-Lys}-L-{d-Leu}-{d-Lys}-KLL-{d-Lys}-LL-NH2 |
| Formula | C90H174N22O15 |
| Molar Mass | 1804.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ben Hur D, et al. Antimicrobial Peptides against Multidrug-Resistant Pseudomonas aeruginosa Biofilm from Cystic Fibrosis Patients. J Med Chem. 2022;65(13):9050-9062. |
D-K6L9
CAS: 426264-61-1 F: C90H174N22O15 W: 1804.48
D-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. D-K6L9 is sta
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.